Sinew Pharma Past Earnings Performance
Past criteria checks 0/6
Sinew Pharma's earnings have been declining at an average annual rate of -18.5%, while the Pharmaceuticals industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 15.2% per year.
Key information
-18.5%
Earnings growth rate
-2.2%
EPS growth rate
Pharmaceuticals Industry Growth | 18.5% |
Revenue growth rate | 15.2% |
Return on equity | -12.9% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses Breakdown
How Sinew Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -171 | 35 | 152 |
30 Sep 23 | 0 | -158 | 34 | 138 |
30 Jun 23 | 0 | -145 | 33 | 124 |
31 Mar 23 | 0 | -142 | 33 | 119 |
31 Dec 22 | 0 | -140 | 34 | 115 |
30 Sep 22 | 1 | -128 | 34 | 102 |
30 Jun 22 | 2 | -116 | 33 | 89 |
31 Mar 22 | 4 | -104 | 30 | 81 |
31 Dec 21 | 6 | -92 | 27 | 73 |
30 Sep 21 | 6 | -86 | 24 | 70 |
30 Jun 21 | 6 | -81 | 21 | 67 |
31 Mar 21 | 3 | -82 | 19 | 67 |
31 Dec 20 | 0 | -82 | 18 | 67 |
30 Sep 20 | 0 | -81 | 17 | 65 |
30 Jun 20 | 0 | -80 | 17 | 64 |
31 Mar 20 | 0 | -78 | 17 | 62 |
31 Dec 19 | 0 | -76 | 17 | 60 |
30 Sep 19 | 0 | -75 | 16 | 59 |
30 Jun 19 | 0 | -73 | 16 | 59 |
31 Mar 19 | 0 | -74 | 16 | 59 |
31 Dec 18 | 0 | -74 | 16 | 60 |
30 Sep 18 | 0 | -76 | 15 | 63 |
30 Jun 18 | 0 | -77 | 15 | 66 |
31 Mar 18 | 0 | -80 | 16 | 67 |
31 Dec 17 | 0 | -82 | 17 | 68 |
30 Sep 17 | 0 | -80 | 17 | 65 |
30 Jun 17 | 0 | -78 | 17 | 63 |
31 Mar 17 | 0 | -73 | 16 | 58 |
31 Dec 16 | 0 | -67 | 14 | 54 |
31 Dec 15 | 0 | -48 | 3 | 45 |
Quality Earnings: 6634 is currently unprofitable.
Growing Profit Margin: 6634 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6634 is unprofitable, and losses have increased over the past 5 years at a rate of 18.5% per year.
Accelerating Growth: Unable to compare 6634's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6634 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 6634 has a negative Return on Equity (-12.91%), as it is currently unprofitable.